Report Detail

Pharma & Healthcare Global Recombinant Human Granulocyte Colony-Stimulating Factor Injection (rhG-CSF) Market Research Report 2022

  • RnM4438750
  • |
  • 11 May, 2022
  • |
  • Global
  • |
  • 114 Pages
  • |
  • QYResearch
  • |
  • Pharma & Healthcare

Table of Contents

    1 Recombinant Human Granulocyte Colony-Stimulating Factor Injection (rhG-CSF) Market Overview

    • 1.1 Product Overview and Scope of Recombinant Human Granulocyte Colony-Stimulating Factor Injection (rhG-CSF)
    • 1.2 Recombinant Human Granulocyte Colony-Stimulating Factor Injection (rhG-CSF) Segment by Type
      • 1.2.1 Global Recombinant Human Granulocyte Colony-Stimulating Factor Injection (rhG-CSF) Sales Growth Rate Comparison by Type (2022-2028)
      • 1.2.2 Vials
      • 1.2.3 Prefilled
    • 1.3 Recombinant Human Granulocyte Colony-Stimulating Factor Injection (rhG-CSF) Segment by Application
      • 1.3.1 Global Recombinant Human Granulocyte Colony-Stimulating Factor Injection (rhG-CSF) Sales Comparison by Application: (2022-2028)
      • 1.3.2 Myelosuppressive Chemotherapy
      • 1.3.3 Leukemia Chemotherapy
      • 1.3.4 Others
    • 1.4 Global Recombinant Human Granulocyte Colony-Stimulating Factor Injection (rhG-CSF) Market Size Estimates and Forecasts
      • 1.4.1 Global Recombinant Human Granulocyte Colony-Stimulating Factor Injection (rhG-CSF) Revenue 2017-2028
      • 1.4.2 Global Recombinant Human Granulocyte Colony-Stimulating Factor Injection (rhG-CSF) Sales 2017-2028
      • 1.4.3 Recombinant Human Granulocyte Colony-Stimulating Factor Injection (rhG-CSF) Market Size by Region: 2017 Versus 2021 Versus 2028

    2 Recombinant Human Granulocyte Colony-Stimulating Factor Injection (rhG-CSF) Market Competition by Manufacturers

    • 2.1 Global Recombinant Human Granulocyte Colony-Stimulating Factor Injection (rhG-CSF) Sales Market Share by Manufacturers (2017-2022)
    • 2.2 Global Recombinant Human Granulocyte Colony-Stimulating Factor Injection (rhG-CSF) Revenue Market Share by Manufacturers (2017-2022)
    • 2.3 Global Recombinant Human Granulocyte Colony-Stimulating Factor Injection (rhG-CSF) Average Price by Manufacturers (2017-2022)
    • 2.4 Manufacturers Recombinant Human Granulocyte Colony-Stimulating Factor Injection (rhG-CSF) Manufacturing Sites, Area Served, Product Type
    • 2.5 Recombinant Human Granulocyte Colony-Stimulating Factor Injection (rhG-CSF) Market Competitive Situation and Trends
      • 2.5.1 Recombinant Human Granulocyte Colony-Stimulating Factor Injection (rhG-CSF) Market Concentration Rate
      • 2.5.2 The Global Top 5 and Top 10 Largest Recombinant Human Granulocyte Colony-Stimulating Factor Injection (rhG-CSF) Players Market Share by Revenue
      • 2.5.3 Global Recombinant Human Granulocyte Colony-Stimulating Factor Injection (rhG-CSF) Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
    • 2.6 Manufacturers Mergers & Acquisitions, Expansion Plans

    3 Recombinant Human Granulocyte Colony-Stimulating Factor Injection (rhG-CSF) Retrospective Market Scenario by Region

    • 3.1 Global Recombinant Human Granulocyte Colony-Stimulating Factor Injection (rhG-CSF) Retrospective Market Scenario in Sales by Region: 2017-2022
    • 3.2 Global Recombinant Human Granulocyte Colony-Stimulating Factor Injection (rhG-CSF) Retrospective Market Scenario in Revenue by Region: 2017-2022
    • 3.3 North America Recombinant Human Granulocyte Colony-Stimulating Factor Injection (rhG-CSF) Market Facts & Figures by Country
      • 3.3.1 North America Recombinant Human Granulocyte Colony-Stimulating Factor Injection (rhG-CSF) Sales by Country
      • 3.3.2 North America Recombinant Human Granulocyte Colony-Stimulating Factor Injection (rhG-CSF) Revenue by Country
      • 3.3.3 United States
      • 3.3.4 Canada
    • 3.4 Europe Recombinant Human Granulocyte Colony-Stimulating Factor Injection (rhG-CSF) Market Facts & Figures by Country
      • 3.4.1 Europe Recombinant Human Granulocyte Colony-Stimulating Factor Injection (rhG-CSF) Sales by Country
      • 3.4.2 Europe Recombinant Human Granulocyte Colony-Stimulating Factor Injection (rhG-CSF) Revenue by Country
      • 3.4.3 Germany
      • 3.4.4 France
      • 3.4.5 U.K.
      • 3.4.6 Italy
      • 3.4.7 Russia
    • 3.5 Asia Pacific Recombinant Human Granulocyte Colony-Stimulating Factor Injection (rhG-CSF) Market Facts & Figures by Region
      • 3.5.1 Asia Pacific Recombinant Human Granulocyte Colony-Stimulating Factor Injection (rhG-CSF) Sales by Region
      • 3.5.2 Asia Pacific Recombinant Human Granulocyte Colony-Stimulating Factor Injection (rhG-CSF) Revenue by Region
      • 3.5.3 China
      • 3.5.4 Japan
      • 3.5.5 South Korea
      • 3.5.6 India
      • 3.5.7 Australia
      • 3.5.8 China Taiwan
      • 3.5.9 Indonesia
      • 3.5.10 Thailand
      • 3.5.11 Malaysia
    • 3.6 Latin America Recombinant Human Granulocyte Colony-Stimulating Factor Injection (rhG-CSF) Market Facts & Figures by Country
      • 3.6.1 Latin America Recombinant Human Granulocyte Colony-Stimulating Factor Injection (rhG-CSF) Sales by Country
      • 3.6.2 Latin America Recombinant Human Granulocyte Colony-Stimulating Factor Injection (rhG-CSF) Revenue by Country
      • 3.6.3 Mexico
      • 3.6.4 Brazil
      • 3.6.5 Argentina
    • 3.7 Middle East and Africa Recombinant Human Granulocyte Colony-Stimulating Factor Injection (rhG-CSF) Market Facts & Figures by Country
      • 3.7.1 Middle East and Africa Recombinant Human Granulocyte Colony-Stimulating Factor Injection (rhG-CSF) Sales by Country
      • 3.7.2 Middle East and Africa Recombinant Human Granulocyte Colony-Stimulating Factor Injection (rhG-CSF) Revenue by Country
      • 3.7.3 Turkey
      • 3.7.4 Saudi Arabia
      • 3.7.5 UAE

    4 Global Recombinant Human Granulocyte Colony-Stimulating Factor Injection (rhG-CSF) Historic Market Analysis by Type

    • 4.1 Global Recombinant Human Granulocyte Colony-Stimulating Factor Injection (rhG-CSF) Sales Market Share by Type (2017-2022)
    • 4.2 Global Recombinant Human Granulocyte Colony-Stimulating Factor Injection (rhG-CSF) Revenue Market Share by Type (2017-2022)
    • 4.3 Global Recombinant Human Granulocyte Colony-Stimulating Factor Injection (rhG-CSF) Price by Type (2017-2022)

    5 Global Recombinant Human Granulocyte Colony-Stimulating Factor Injection (rhG-CSF) Historic Market Analysis by Application

    • 5.1 Global Recombinant Human Granulocyte Colony-Stimulating Factor Injection (rhG-CSF) Sales Market Share by Application (2017-2022)
    • 5.2 Global Recombinant Human Granulocyte Colony-Stimulating Factor Injection (rhG-CSF) Revenue Market Share by Application (2017-2022)
    • 5.3 Global Recombinant Human Granulocyte Colony-Stimulating Factor Injection (rhG-CSF) Price by Application (2017-2022)

    6 Key Companies Profiled

    • 6.1 Abbott
      • 6.1.1 Abbott Corporation Information
      • 6.1.2 Abbott Description and Business Overview
      • 6.1.3 Abbott Recombinant Human Granulocyte Colony-Stimulating Factor Injection (rhG-CSF) Sales, Revenue and Gross Margin (2017-2022)
      • 6.1.4 Abbott Recombinant Human Granulocyte Colony-Stimulating Factor Injection (rhG-CSF) Product Portfolio
      • 6.1.5 Abbott Recent Developments/Updates
    • 6.2 Amgen
      • 6.2.1 Amgen Corporation Information
      • 6.2.2 Amgen Description and Business Overview
      • 6.2.3 Amgen Recombinant Human Granulocyte Colony-Stimulating Factor Injection (rhG-CSF) Sales, Revenue and Gross Margin (2017-2022)
      • 6.2.4 Amgen Recombinant Human Granulocyte Colony-Stimulating Factor Injection (rhG-CSF) Product Portfolio
      • 6.2.5 Amgen Recent Developments/Updates
    • 6.3 Arven Pharmaceuticals
      • 6.3.1 Arven Pharmaceuticals Corporation Information
      • 6.3.2 Arven Pharmaceuticals Description and Business Overview
      • 6.3.3 Arven Pharmaceuticals Recombinant Human Granulocyte Colony-Stimulating Factor Injection (rhG-CSF) Sales, Revenue and Gross Margin (2017-2022)
      • 6.3.4 Arven Pharmaceuticals Recombinant Human Granulocyte Colony-Stimulating Factor Injection (rhG-CSF) Product Portfolio
      • 6.3.5 Arven Pharmaceuticals Recent Developments/Updates
    • 6.4 Biocon
      • 6.4.1 Biocon Corporation Information
      • 6.4.2 Biocon Description and Business Overview
      • 6.4.3 Biocon Recombinant Human Granulocyte Colony-Stimulating Factor Injection (rhG-CSF) Sales, Revenue and Gross Margin (2017-2022)
      • 6.4.4 Biocon Recombinant Human Granulocyte Colony-Stimulating Factor Injection (rhG-CSF) Product Portfolio
      • 6.4.5 Biocon Recent Developments/Updates
    • 6.5 Cadila Pharmaceuticals
      • 6.5.1 Cadila Pharmaceuticals Corporation Information
      • 6.5.2 Cadila Pharmaceuticals Description and Business Overview
      • 6.5.3 Cadila Pharmaceuticals Recombinant Human Granulocyte Colony-Stimulating Factor Injection (rhG-CSF) Sales, Revenue and Gross Margin (2017-2022)
      • 6.5.4 Cadila Pharmaceuticals Recombinant Human Granulocyte Colony-Stimulating Factor Injection (rhG-CSF) Product Portfolio
      • 6.5.5 Cadila Pharmaceuticals Recent Developments/Updates
    • 6.6 Dr.Reddy's Laboratories
      • 6.6.1 Dr.Reddy's Laboratories Corporation Information
      • 6.6.2 Dr.Reddy's Laboratories Description and Business Overview
      • 6.6.3 Dr.Reddy's Laboratories Recombinant Human Granulocyte Colony-Stimulating Factor Injection (rhG-CSF) Sales, Revenue and Gross Margin (2017-2022)
      • 6.6.4 Dr.Reddy's Laboratories Recombinant Human Granulocyte Colony-Stimulating Factor Injection (rhG-CSF) Product Portfolio
      • 6.6.5 Dr.Reddy's Laboratories Recent Developments/Updates
    • 6.7 Emcure Pharmaceuticals
      • 6.6.1 Emcure Pharmaceuticals Corporation Information
      • 6.6.2 Emcure Pharmaceuticals Description and Business Overview
      • 6.6.3 Emcure Pharmaceuticals Recombinant Human Granulocyte Colony-Stimulating Factor Injection (rhG-CSF) Sales, Revenue and Gross Margin (2017-2022)
      • 6.4.4 Emcure Pharmaceuticals Recombinant Human Granulocyte Colony-Stimulating Factor Injection (rhG-CSF) Product Portfolio
      • 6.7.5 Emcure Pharmaceuticals Recent Developments/Updates
    • 6.8 Intas Pharmaceuticals
      • 6.8.1 Intas Pharmaceuticals Corporation Information
      • 6.8.2 Intas Pharmaceuticals Description and Business Overview
      • 6.8.3 Intas Pharmaceuticals Recombinant Human Granulocyte Colony-Stimulating Factor Injection (rhG-CSF) Sales, Revenue and Gross Margin (2017-2022)
      • 6.8.4 Intas Pharmaceuticals Recombinant Human Granulocyte Colony-Stimulating Factor Injection (rhG-CSF) Product Portfolio
      • 6.8.5 Intas Pharmaceuticals Recent Developments/Updates
    • 6.9 Kyowa Kirin
      • 6.9.1 Kyowa Kirin Corporation Information
      • 6.9.2 Kyowa Kirin Description and Business Overview
      • 6.9.3 Kyowa Kirin Recombinant Human Granulocyte Colony-Stimulating Factor Injection (rhG-CSF) Sales, Revenue and Gross Margin (2017-2022)
      • 6.9.4 Kyowa Kirin Recombinant Human Granulocyte Colony-Stimulating Factor Injection (rhG-CSF) Product Portfolio
      • 6.9.5 Kyowa Kirin Recent Developments/Updates
    • 6.10 Novartis
      • 6.10.1 Novartis Corporation Information
      • 6.10.2 Novartis Description and Business Overview
      • 6.10.3 Novartis Recombinant Human Granulocyte Colony-Stimulating Factor Injection (rhG-CSF) Sales, Revenue and Gross Margin (2017-2022)
      • 6.10.4 Novartis Recombinant Human Granulocyte Colony-Stimulating Factor Injection (rhG-CSF) Product Portfolio
      • 6.10.5 Novartis Recent Developments/Updates
    • 6.11 Pfizer
      • 6.11.1 Pfizer Corporation Information
      • 6.11.2 Pfizer Recombinant Human Granulocyte Colony-Stimulating Factor Injection (rhG-CSF) Description and Business Overview
      • 6.11.3 Pfizer Recombinant Human Granulocyte Colony-Stimulating Factor Injection (rhG-CSF) Sales, Revenue and Gross Margin (2017-2022)
      • 6.11.4 Pfizer Recombinant Human Granulocyte Colony-Stimulating Factor Injection (rhG-CSF) Product Portfolio
      • 6.11.5 Pfizer Recent Developments/Updates
    • 6.12 Reliance Life Sciences
      • 6.12.1 Reliance Life Sciences Corporation Information
      • 6.12.2 Reliance Life Sciences Recombinant Human Granulocyte Colony-Stimulating Factor Injection (rhG-CSF) Description and Business Overview
      • 6.12.3 Reliance Life Sciences Recombinant Human Granulocyte Colony-Stimulating Factor Injection (rhG-CSF) Sales, Revenue and Gross Margin (2017-2022)
      • 6.12.4 Reliance Life Sciences Recombinant Human Granulocyte Colony-Stimulating Factor Injection (rhG-CSF) Product Portfolio
      • 6.12.5 Reliance Life Sciences Recent Developments/Updates
    • 6.13 Harbin Pharmaceutical
      • 6.13.1 Harbin Pharmaceutical Corporation Information
      • 6.13.2 Harbin Pharmaceutical Recombinant Human Granulocyte Colony-Stimulating Factor Injection (rhG-CSF) Description and Business Overview
      • 6.13.3 Harbin Pharmaceutical Recombinant Human Granulocyte Colony-Stimulating Factor Injection (rhG-CSF) Sales, Revenue and Gross Margin (2017-2022)
      • 6.13.4 Harbin Pharmaceutical Recombinant Human Granulocyte Colony-Stimulating Factor Injection (rhG-CSF) Product Portfolio
      • 6.13.5 Harbin Pharmaceutical Recent Developments/Updates
    • 6.14 North China Pharmaceutical
      • 6.14.1 North China Pharmaceutical Corporation Information
      • 6.14.2 North China Pharmaceutical Recombinant Human Granulocyte Colony-Stimulating Factor Injection (rhG-CSF) Description and Business Overview
      • 6.14.3 North China Pharmaceutical Recombinant Human Granulocyte Colony-Stimulating Factor Injection (rhG-CSF) Sales, Revenue and Gross Margin (2017-2022)
      • 6.14.4 North China Pharmaceutical Recombinant Human Granulocyte Colony-Stimulating Factor Injection (rhG-CSF) Product Portfolio
      • 6.14.5 North China Pharmaceutical Recent Developments/Updates
    • 6.15 Jiuyuan Gene
      • 6.15.1 Jiuyuan Gene Corporation Information
      • 6.15.2 Jiuyuan Gene Recombinant Human Granulocyte Colony-Stimulating Factor Injection (rhG-CSF) Description and Business Overview
      • 6.15.3 Jiuyuan Gene Recombinant Human Granulocyte Colony-Stimulating Factor Injection (rhG-CSF) Sales, Revenue and Gross Margin (2017-2022)
      • 6.15.4 Jiuyuan Gene Recombinant Human Granulocyte Colony-Stimulating Factor Injection (rhG-CSF) Product Portfolio
      • 6.15.5 Jiuyuan Gene Recent Developments/Updates
    • 6.16 Kexing Biopharm
      • 6.16.1 Kexing Biopharm Corporation Information
      • 6.16.2 Kexing Biopharm Recombinant Human Granulocyte Colony-Stimulating Factor Injection (rhG-CSF) Description and Business Overview
      • 6.16.3 Kexing Biopharm Recombinant Human Granulocyte Colony-Stimulating Factor Injection (rhG-CSF) Sales, Revenue and Gross Margin (2017-2022)
      • 6.16.4 Kexing Biopharm Recombinant Human Granulocyte Colony-Stimulating Factor Injection (rhG-CSF) Product Portfolio
      • 6.16.5 Kexing Biopharm Recent Developments/Updates
    • 6.17 Qilu Pharmaceutical
      • 6.17.1 Qilu Pharmaceutical Corporation Information
      • 6.17.2 Qilu Pharmaceutical Recombinant Human Granulocyte Colony-Stimulating Factor Injection (rhG-CSF) Description and Business Overview
      • 6.17.3 Qilu Pharmaceutical Recombinant Human Granulocyte Colony-Stimulating Factor Injection (rhG-CSF) Sales, Revenue and Gross Margin (2017-2022)
      • 6.17.4 Qilu Pharmaceutical Recombinant Human Granulocyte Colony-Stimulating Factor Injection (rhG-CSF) Product Portfolio
      • 6.17.5 Qilu Pharmaceutical Recent Developments/Updates
    • 6.18 Quangang Pharmaceutical
      • 6.18.1 Quangang Pharmaceutical Corporation Information
      • 6.18.2 Quangang Pharmaceutical Recombinant Human Granulocyte Colony-Stimulating Factor Injection (rhG-CSF) Description and Business Overview
      • 6.18.3 Quangang Pharmaceutical Recombinant Human Granulocyte Colony-Stimulating Factor Injection (rhG-CSF) Sales, Revenue and Gross Margin (2017-2022)
      • 6.18.4 Quangang Pharmaceutical Recombinant Human Granulocyte Colony-Stimulating Factor Injection (rhG-CSF) Product Portfolio
      • 6.18.5 Quangang Pharmaceutical Recent Developments/Updates
    • 6.19 Sunway Biotech
      • 6.19.1 Sunway Biotech Corporation Information
      • 6.19.2 Sunway Biotech Recombinant Human Granulocyte Colony-Stimulating Factor Injection (rhG-CSF) Description and Business Overview
      • 6.19.3 Sunway Biotech Recombinant Human Granulocyte Colony-Stimulating Factor Injection (rhG-CSF) Sales, Revenue and Gross Margin (2017-2022)
      • 6.19.4 Sunway Biotech Recombinant Human Granulocyte Colony-Stimulating Factor Injection (rhG-CSF) Product Portfolio
      • 6.19.5 Sunway Biotech Recent Developments/Updates
    • 6.20 SL Pharmaceutical
      • 6.20.1 SL Pharmaceutical Corporation Information
      • 6.20.2 SL Pharmaceutical Recombinant Human Granulocyte Colony-Stimulating Factor Injection (rhG-CSF) Description and Business Overview
      • 6.20.3 SL Pharmaceutical Recombinant Human Granulocyte Colony-Stimulating Factor Injection (rhG-CSF) Sales, Revenue and Gross Margin (2017-2022)
      • 6.20.4 SL Pharmaceutical Recombinant Human Granulocyte Colony-Stimulating Factor Injection (rhG-CSF) Product Portfolio
      • 6.20.5 SL Pharmaceutical Recent Developments/Updates
    • 6.21 Four Rings Bio-Pharmaceutical
      • 6.21.1 Four Rings Bio-Pharmaceutical Corporation Information
      • 6.21.2 Four Rings Bio-Pharmaceutical Recombinant Human Granulocyte Colony-Stimulating Factor Injection (rhG-CSF) Description and Business Overview
      • 6.21.3 Four Rings Bio-Pharmaceutical Recombinant Human Granulocyte Colony-Stimulating Factor Injection (rhG-CSF) Sales, Revenue and Gross Margin (2017-2022)
      • 6.21.4 Four Rings Bio-Pharmaceutical Recombinant Human Granulocyte Colony-Stimulating Factor Injection (rhG-CSF) Product Portfolio
      • 6.21.5 Four Rings Bio-Pharmaceutical Recent Developments/Updates
    • 6.22 Amoytop
      • 6.22.1 Amoytop Corporation Information
      • 6.22.2 Amoytop Recombinant Human Granulocyte Colony-Stimulating Factor Injection (rhG-CSF) Description and Business Overview
      • 6.22.3 Amoytop Recombinant Human Granulocyte Colony-Stimulating Factor Injection (rhG-CSF) Sales, Revenue and Gross Margin (2017-2022)
      • 6.22.4 Amoytop Recombinant Human Granulocyte Colony-Stimulating Factor Injection (rhG-CSF) Product Portfolio
      • 6.22.5 Amoytop Recent Developments/Updates
    • 6.23 Wuzhong Pharmaceutical
      • 6.23.1 Wuzhong Pharmaceutical Corporation Information
      • 6.23.2 Wuzhong Pharmaceutical Recombinant Human Granulocyte Colony-Stimulating Factor Injection (rhG-CSF) Description and Business Overview
      • 6.23.3 Wuzhong Pharmaceutical Recombinant Human Granulocyte Colony-Stimulating Factor Injection (rhG-CSF) Sales, Revenue and Gross Margin (2017-2022)
      • 6.23.4 Wuzhong Pharmaceutical Recombinant Human Granulocyte Colony-Stimulating Factor Injection (rhG-CSF) Product Portfolio
      • 6.23.5 Wuzhong Pharmaceutical Recent Developments/Updates

    7 Recombinant Human Granulocyte Colony-Stimulating Factor Injection (rhG-CSF) Manufacturing Cost Analysis

    • 7.1 Recombinant Human Granulocyte Colony-Stimulating Factor Injection (rhG-CSF) Key Raw Materials Analysis
      • 7.1.1 Key Raw Materials
      • 7.1.2 Key Suppliers of Raw Materials
    • 7.2 Proportion of Manufacturing Cost Structure
    • 7.3 Manufacturing Process Analysis of Recombinant Human Granulocyte Colony-Stimulating Factor Injection (rhG-CSF)
    • 7.4 Recombinant Human Granulocyte Colony-Stimulating Factor Injection (rhG-CSF) Industrial Chain Analysis

    8 Marketing Channel, Distributors and Customers

    • 8.1 Marketing Channel
    • 8.2 Recombinant Human Granulocyte Colony-Stimulating Factor Injection (rhG-CSF) Distributors List
    • 8.3 Recombinant Human Granulocyte Colony-Stimulating Factor Injection (rhG-CSF) Customers

    9 Recombinant Human Granulocyte Colony-Stimulating Factor Injection (rhG-CSF) Market Dynamics

    • 9.1 Recombinant Human Granulocyte Colony-Stimulating Factor Injection (rhG-CSF) Industry Trends
    • 9.2 Recombinant Human Granulocyte Colony-Stimulating Factor Injection (rhG-CSF) Market Drivers
    • 9.3 Recombinant Human Granulocyte Colony-Stimulating Factor Injection (rhG-CSF) Market Challenges
    • 9.4 Recombinant Human Granulocyte Colony-Stimulating Factor Injection (rhG-CSF) Market Restraints

    10 Global Market Forecast

    • 10.1 Recombinant Human Granulocyte Colony-Stimulating Factor Injection (rhG-CSF) Market Estimates and Projections by Type
      • 10.1.1 Global Forecasted Sales of Recombinant Human Granulocyte Colony-Stimulating Factor Injection (rhG-CSF) by Type (2023-2028)
      • 10.1.2 Global Forecasted Revenue of Recombinant Human Granulocyte Colony-Stimulating Factor Injection (rhG-CSF) by Type (2023-2028)
    • 10.2 Recombinant Human Granulocyte Colony-Stimulating Factor Injection (rhG-CSF) Market Estimates and Projections by Application
      • 10.2.1 Global Forecasted Sales of Recombinant Human Granulocyte Colony-Stimulating Factor Injection (rhG-CSF) by Application (2023-2028)
      • 10.2.2 Global Forecasted Revenue of Recombinant Human Granulocyte Colony-Stimulating Factor Injection (rhG-CSF) by Application (2023-2028)
    • 10.3 Recombinant Human Granulocyte Colony-Stimulating Factor Injection (rhG-CSF) Market Estimates and Projections by Region
      • 10.3.1 Global Forecasted Sales of Recombinant Human Granulocyte Colony-Stimulating Factor Injection (rhG-CSF) by Region (2023-2028)
      • 10.3.2 Global Forecasted Revenue of Recombinant Human Granulocyte Colony-Stimulating Factor Injection (rhG-CSF) by Region (2023-2028)

    11 Research Finding and Conclusion

      12 Methodology and Data Source

      • 12.1 Methodology/Research Approach
        • 12.1.1 Research Programs/Design
        • 12.1.2 Market Size Estimation
        • 12.1.3 Market Breakdown and Data Triangulation
      • 12.2 Data Source
        • 12.2.1 Secondary Sources
        • 12.2.2 Primary Sources
      • 12.3 Author List

      Summary:

      Industry Insights
      Due to the COVID-19 pandemic, the global Recombinant Human Granulocyte Colony-Stimulating Factor Injection (rhG-CSF) market size is estimated to be worth US$ million in 2021 and is forecast to a readjusted size of US$ million by 2028 with a CAGR of % during the forecast period 2022-2028. Fully considering the economic change by this health crisis, the Europe Recombinant Human Granulocyte Colony-Stimulating Factor Injection (rhG-CSF) market is estimated at US$ million in 2022, while the United States and China are forecast to reach US$ million and US$ million by 2028, respectively. The proportion of the United States is % in 2022, while Chinese percentage is %, and it is predicted that China market share will reach % in 2028, trailing a CAGR of % through the analysis period. As for the Europe Recombinant Human Granulocyte Colony-Stimulating Factor Injection (rhG-CSF) landscape, Germany is projected to reach US$ million by 2028. and in Asia, the notable markets are Japan and South Korea, CAGR is % and % respectively for the next 6-year period.
      Vials accounting for % of the Recombinant Human Granulocyte Colony-Stimulating Factor Injection (rhG-CSF) global market in 2021, is projected to value US$ million by 2028, growing at a revised % CAGR from 2022 to 2028. While Myelosuppressive Chemotherapy segment is altered to an % CAGR throughout this forecast period and will hold a share about % in 2028.
      The global major manufacturers of Recombinant Human Granulocyte Colony-Stimulating Factor Injection (rhG-CSF) include Abbott, Amgen, Arven Pharmaceuticals, Biocon, Cadila Pharmaceuticals, Dr.Reddy's Laboratories, Emcure Pharmaceuticals, Intas Pharmaceuticals and Kyowa Kirin, etc. In terms of revenue, the global 3 largest players have a % market share of Recombinant Human Granulocyte Colony-Stimulating Factor Injection (rhG-CSF) in 2021.
      This report focuses on Recombinant Human Granulocyte Colony-Stimulating Factor Injection (rhG-CSF) volume and value at the global level, regional level, and company level. From a global perspective, this report represents overall Recombinant Human Granulocyte Colony-Stimulating Factor Injection (rhG-CSF) market size by analysing historical data and future prospect. Regionally, this report focuses on several key regions: North America, Europe, China and Japan, etc.
      Key Drivers & Barriers
      High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.
      Post-covid-19 Outlook
      The readers in the section will understand how the Recombinant Human Granulocyte Colony-Stimulating Factor Injection (rhG-CSF) market scenario changed across the globe during the pandemic and post-pandemic. The study is done keeping in view the changes in aspects such as sales, demand and supply chain. The industry experts have also highlighted the key factors that will help create opportunities for players and stabilize the overall industry in the years to come.
      Segmental Outlook
      Key segments including type and application have been elaborated in this report. The consultants at QY Research have studied every segment and provided the market size using historical data. They have also talked about the growth opportunities that the segment may pose in the future. This study bestows sales and revenue data by type, and application during the historical period (2017-2022) and forecast period (2023-2028).
      Segment by Type
      Vials
      Prefilled
      Segment by Application
      Myelosuppressive Chemotherapy
      Leukemia Chemotherapy
      Others
      Regional Outlook
      This section of the report provides key insights regarding various regions and the key players operating in each region. Economic, social, environmental, technological, and political factors have been taken into consideration while assessing the growth of the particular region/country. The readers will also get their hands on the revenue and sales data of each region and country for the period 2017-2028. This information derived through comprehensive research will help the reader to get familiar with the potential value of the investment in a particular region.
      North America
      United States
      Canada
      Europe
      Germany
      France
      U.K.
      Italy
      Russia
      Asia-Pacific
      China
      Japan
      South Korea
      India
      Australia
      China Taiwan
      Indonesia
      Thailand
      Malaysia
      Latin America
      Mexico
      Brazil
      Argentina
      Middle East & Africa
      Turkey
      Saudi Arabia
      UAE
      Competitive Scenario
      In this section, the readers will gain an understanding of the key players competing. The experts at QY Research have studied the key growth strategies, such as innovative trends and developments, intensification of product portfolio, mergers and acquisitions, collaborations, new product innovation, and geographical expansion, undertaken by these participants to maintain their presence. Apart from business strategies, the study includes current developments and key financials. The readers will also get access to the data related to global revenue, price, and sales by manufacturers for the period 2017-2022. This all-inclusive report will certainly serve the clients to stay updated and make effective decisions in their businesses. Some of the prominent players reviewed in the research report include:
      Abbott
      Amgen
      Arven Pharmaceuticals
      Biocon
      Cadila Pharmaceuticals
      Dr.Reddy's Laboratories
      Emcure Pharmaceuticals
      Intas Pharmaceuticals
      Kyowa Kirin
      Novartis
      Pfizer
      Reliance Life Sciences
      Harbin Pharmaceutical
      North China Pharmaceutical
      Jiuyuan Gene
      Kexing Biopharm
      Qilu Pharmaceutical
      Quangang Pharmaceutical
      Sunway Biotech
      SL Pharmaceutical
      Four Rings Bio-Pharmaceutical
      Amoytop
      Wuzhong Pharmaceutical
      Frequently Asked Questions
      Which product segment grabbed the largest share in the Recombinant Human Granulocyte Colony-Stimulating Factor Injection (rhG-CSF) market?
      How is the competitive scenario of the Recombinant Human Granulocyte Colony-Stimulating Factor Injection (rhG-CSF) market?
      Which are the key factors aiding the Recombinant Human Granulocyte Colony-Stimulating Factor Injection (rhG-CSF) market growth?
      Which are the prominent players in the Recombinant Human Granulocyte Colony-Stimulating Factor Injection (rhG-CSF) market?
      Which region holds the maximum share in the Recombinant Human Granulocyte Colony-Stimulating Factor Injection (rhG-CSF) market?
      What will be the CAGR of the Recombinant Human Granulocyte Colony-Stimulating Factor Injection (rhG-CSF) market during the forecast period?
      Which application segment emerged as the leading segment in the Recombinant Human Granulocyte Colony-Stimulating Factor Injection (rhG-CSF) market?
      What key trends are likely to emerge in the Recombinant Human Granulocyte Colony-Stimulating Factor Injection (rhG-CSF) market in the coming years?
      What will be the Recombinant Human Granulocyte Colony-Stimulating Factor Injection (rhG-CSF) market size by 2028?
      Which company held the largest share in the Recombinant Human Granulocyte Colony-Stimulating Factor Injection (rhG-CSF) market?


      Summary:
      Get latest Market Research Reports on Recombinant Human Granulocyte Colony-Stimulating Factor Injection (rhG-CSF). Industry analysis & Market Report on Recombinant Human Granulocyte Colony-Stimulating Factor Injection (rhG-CSF) is a syndicated market report, published as Global Recombinant Human Granulocyte Colony-Stimulating Factor Injection (rhG-CSF) Market Research Report 2022. It is complete Research Study and Industry Analysis of Recombinant Human Granulocyte Colony-Stimulating Factor Injection (rhG-CSF) market, to understand, Market Demand, Growth, trends analysis and Factor Influencing market.

      Last updated on

      REPORT YOU MIGHT BE INTERESTED

      Purchase this Report

      $2,900.00
      $5,800.00
      2,343.20
      4,686.40
      2,763.70
      5,527.40
      372,418.00
      744,836.00
      225,011.00
      450,022.00
      Credit card Logo

      Related Reports


      Reason to Buy

      Request for Sample of this report